Nine stocks posted strong gains on Thursday, bucking a mixed performance in the broader market, driven by positive company-specific developments that boosted buying appetite. The list was notably dominated by biopharmaceutical stocks.

Meanwhile, only the Dow Jones and the S&P 500 finished in the green, climbing 1.73 percent and 0.41 percent, respectively. The Nasdaq dropped by 0.09 percent.

Indices aside, we name the 10 top-performing companies during the session and break down the reasons behind their gains.

To come up with the list, we considered the stocks with a market capitalization of $2 billion and 5 million shares in trading volume.

9. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)

Recursion Pharmaceuticals snapped two straight days of losses on Thursday, surging 9.51 percent to close at $3.80 as investors began repositioning portfolios ahead of key business updates next week.

In a notice to investors, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) said that it is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, where investors are expected to watch for updates about its pipeline.

One of its pipelines under clinical trial is the REC-4881, an orally available inhibitor to treat familial adenomatous polyposis—a genetically defined disease driven by APC loss.

According to Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), it has initiated an engagement with the Food and Drug Administration to align on a potential registrational study design, with an update expected in the second half of 2026.

In other news, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) posted an improvement in its earnings performance in the first quarter of the year, having slashed its net loss by 42 percent to $117.5 million from $202.5 million in the same period last year.

Total revenues, which come solely from collaboration agreements, fell by 56 percent to $6.47 million from $14.7 million year-on-year due to lower revenues from Roche following the completion of certain project phases in the period earlier.

8. Tempus AI Inc. (NASDAQ:TEM)

Tempus AI saw its share prices jump by 10 percent on Thursday to finish at $52.56 apiece, as investors cheered its formation of a consortium alongside two health institutions to support the development of an open-source digital pathology platform and viewer.

In an updated report, Tempus AI Inc. (NASDAQ:TEM) said that it joined forces with Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK), under which the listed firm will open-source the existing Paige Image Management System to seed the collaborative, open ecosystem. It will operate independently of its current digital pathology commercial offering.

Meanwhile, YNHH and MSK will contribute to defining the vision, governance, and strategic direction of the project.

The parties expect the consortium to add more members over time.

In other news, Tempus AI Inc. (NASDAQ:TEM) also launched on Monday a next-generation sequencing test called xH that uses a whole-genome sequencing approach for the detection of actionable oncologic targets in peripheral blood and bone marrow samples from patients with hematologic malignancies.

Tempus AI Inc. (NASDAQ:TEM) first announced the xH assay for research use only in January 2025. Its performance was established in an analytical validation study using 235 unique specimens, including whole blood, bone marrow, and cell lines.

In addition to high accuracy, the xH assay demonstrated excellent precision, with a positive predictive value of 98.97 percent for single-nucleotide variants and indels, and 100 percent for structural variants. These results indicate a low false-positive rate and support high confidence in the assay’s reported genomic findings.

7. Applied Optoelectronics Inc. (NASDAQ:AAOI)

Applied Optoelectronics saw its share prices increase by 10.22 percent on Thursday to close at $202.89 apiece, buoyed by Nvidia Corp. CEO Jensen Huang’s optimistic comments about the optics industry.

At the ongoing Computex conference in Taiwan, Huang validated the importance of the optics industry in the future of artificial intelligence, saying that the right strategy “is to scale up with copper as long as you can. After that, you scale up further with optics.”

“You scale out with optics, and you scale across with optics. So you use optics wherever you must, you use copper wherever you can,” he noted.

Applied Optoelectronics Inc. (NASDAQ:AAOI) rallied alongside its counterparts, namely Marvell Technology, Credo Technology Group, Coherent Corp., and Lumentum Holdings, among others.

Further boosting sentiment was Rosenblatt’s highly optimistic outlook for the sector, saying that it expects key players to expand production capacities by approximately 12x through 2030 to support the growing demands from AI.

However, it noted the expansion rate will remain slower than the rapid demand growth from AI.

Rosenblatt noted that last year alone, the supply of indium phosphide-based Datacom components lagged by 50 percent. However, this gives room for huge growth and expansion opportunities for key players such as Applied Optoelectronics Inc. (NASDAQ:AAOI).

For its part, Applied Optoelectronics Inc. (NASDAQ:AAOI) is underway with the expansion of its new manufacturing facility in SugarLand, Texas, as it aims to support the growing needs of its customers.

The company initially programmed $150 million in capital expenditures for the site development, and later doubled it to $300 million by the end of 2027.

6. Intellia Therapeutics Inc. (NASDAQ:NTLA)

Intellia Therapeutics snapped a three-day losing streak on Thursday, soaring 13.29 percent to close at $14.75 apiece, as investors positioned portfolios ahead of the phase 3 results of its lonvo-z study in hereditary angioedema (HAE).

In a notice on its website, Intellia Therapeutics Inc. (NASDAQ:NTLA) said that it would present the late-breaking results at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Turkiye on June 12-15.

Lonvo-z is an experimental gene-editing therapy designed as a potential one-time functional cure for HAE, a rare, painful, and potentially fatal genetic condition that causes sudden, severe swelling in the face, limbs, and airways.

In April this year, Intellia Therapeutics Inc. (NASDAQ:NTLA) submitted a biologics license application with the Food and Drug Administration for the approval of lonvo-z following positive topline data, having met its primary and all key secondary endpoints.

“If approved, lonvo-z will become the world’s first in vivo CRISPR-based gene editing therapy,” Intellia Therapeutics Inc. (NASDAQ:NTLA) President and CEO John Leonard said.

“The promising results … reinforce our conviction that lonvo-z could revolutionize how HAE is treated for many patients, with the potential to free most of them from both attacks and the need for ongoing therapy with just one dose. We look forward to our continued engagement with the FDA as we seek to ease many of the burdens for people living with HAE,” he noted.

Click to continue reading and see the other 5 Stocks Crushing the Market With Surging Returns.

Disclosure: None. Follow Insider Monkey on Google News.